Inozyme Pharma/INZY

$4.65

0.21%
-
1D1W1MYTD1YMAX

About Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.

Ticker

INZY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Douglas Treco

Employees

59

Headquarters

Boston, United States
Website
www.inozyme.com

Inozyme Pharma Metrics

BasicAdvanced
$287M
Market cap
-
P/E ratio
-$1.37
EPS
1.54
Beta
-
Dividend rate
$287M
1.54013
$7.80
$2.69
690K
14.052
37.894
37.894
-48.39%
-69.41%
-52.5%
2.414
2.412
13.56%

What the Analysts think about Inozyme Pharma

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
337.2% upside
High $40.00
Low $14.00
$4.65
Current price
$20.33
Average price target

Inozyme Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
8.37%
Profit margin
0%
NaN%

Inozyme Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 5.56%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.29
-$0.33
-$0.38
-
Expected
-$0.43
-$0.32
-$0.32
-$0.36
-$0.38
Surprise
-19.17%
-8.31%
3.59%
5.56%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Inozyme Pharma stock?

Inozyme Pharma (INZY) has a market cap of $280M as of May 12, 2024.

What is the P/E ratio for Inozyme Pharma stock?

The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of May 12, 2024.

Does Inozyme Pharma stock pay dividends?

No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of May 12, 2024.

When is the next Inozyme Pharma dividend payment date?

Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.

What is the beta indicator for Inozyme Pharma?

Inozyme Pharma (INZY) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Inozyme Pharma stock price target?

The target price for Inozyme Pharma (INZY) stock is $20.33, which is 347.8% above the current price of $4.54. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Inozyme Pharma stock

Buy or sell Inozyme Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing